To read all of these articles and more, visit centerforbiosimilars.com.

Four biosimilars for Stelara have launched in the United States this year following legal settlements with the reference ...

Switching between infliximab biosimilar SB2 and the reference product ... According to the investigators, “the initial and the reverse switch had no relevant impact on the course of disease ...

Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 ...

The FDA has approved Stoboclo (denosumab-bmwo), a biosimilar to Prolia (denosumab), and Osenvelt (denosumab-bmwo), a biosimilar to Xgeva (denosumab).

Celltrion, Inc., a leading global biopharmaceutical company, announced today that its infliximab biosimilar will be marketed in Canada under the new b ...

Optimizing Humira coverage is not just about reducing costs—it's about delivering effective, compassionate care while ...

STEQEYMA®, one of the first-wave biosimilars to STELARA®, is now available in the U.S. Approved for the same indications as ...

Patients who received the biosimilar in the first period continued to do so at week 52; those who received Prolia were randomly assigned to continue the treatment or switch to the biosimilar ...

Patients who have been on Inflectra can continue their therapy without any need to switch between different biosimilars, ensuring consistency in their care during this transition.” Celltrion ...